Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
|
31754113 |
2019 |
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We show that MYC or MYCN amplification in patient-derived glioblastoma stem-like cells (GSCs) generates sensitivity to PARPi via Myc-mediated transcriptional repression of CDK18, while most tumors without amplification are not sensitive.
|
31266951 |
2019 |
Glioblastoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
TAp63 represses transcription of MYC oncogene in glioblastomas; however, its role in another MYC family gene, MYCN, has remained elusive.
|
31427086 |
2019 |
Glioblastoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Here we report that ASCL1 not only promotes the acquisition of a PN phenotype in CSCs by inducing a glial-to-neuronal lineage switch but also concomitantly represses mesenchymal (MES) features by directly downregulating the expression of N-Myc downstream-regulated gene 1 (NDRG1), which we propose as a novel gene classifier of MES GBMs.
|
30538287 |
2019 |
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Inhibition of repair processes and comparison of the mouse tumors with human medulloblastomas (n = 68) and glioblastomas (n = 32) identified chromothripsis as associated with MYC/MYCN gains and with DNA repair deficiencies, pointing towards therapeutic opportunities to target DNA repair defects in tumors with complex genomic rearrangements.
|
30420702 |
2018 |
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
NAMPT inhibitors were potently cytotoxic, inducing apoptosis and significantly extended the survival of mice bearing MYCN-amplified patient-derived glioblastoma orthotopic xenografts.
|
27076630 |
2016 |
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We provide the mechanistic explanation for how the fi rst histone gene mutation inhuman disease biology acts to deliver MYCN, a potent tumorigenic initiator, into a stem-cell compartment of the developing forebrain, selectively giving rise to incurable cerebral hemispheric GBM.
|
23539269 |
2013 |
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
NDRG2, a member of the N-Myc downstream-regulated gene family, was shown to be a putative tumor suppressor gene in glioblastoma and other cancers.
|
21912936 |
2012 |
Glioblastoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This finding also confirms the importance of impairment of the MYC/MAX/MXD1 axis in the development of aggressive neural tumors, because MYCN overexpression is an established genetic hallmark of malign neuroblastoma, and it is likely that MXI1 plays a relevant role in the development of medulloblastoma and glioblastoma.
|
22706201 |
2012 |
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation.
|
12845671 |
2003 |
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In the glioblastomas with no alterations of CDKN2A, CDK4 or RB1, several other genes (CCND1, CCND2, CCND3, CDK6, E2F, CDK7, MYC and MYCN) whose products take part in cell cycle regulation were examined.No abnormalities were detected.
|
8806696 |
1996 |
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Four genes have been identified as being amplified in more than single cases of glioblastomas; MYCN, GLI, PDGFRA and EGFR.
|
8448375 |
1993 |
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Gene amplification and rearrangements are discussed through review of recent work on the N-myc gene in neuroblastoma and the epidermal growth factor receptor (EGFR) gene in glioblastoma.
|
3059215 |
1988 |